434,919 Shares in Pfizer Inc. (NYSE:PFE) Bought by Generali Asset Management SPA SGR

Generali Asset Management SPA SGR bought a new position in shares of Pfizer Inc. (NYSE:PFE - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 434,919 shares of the biopharmaceutical company's stock, valued at approximately $11,538,000.

Other institutional investors have also recently made changes to their positions in the company. Charles Schwab Investment Management Inc. grew its position in shares of Pfizer by 11.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 130,143,942 shares of the biopharmaceutical company's stock worth $3,766,366,000 after purchasing an additional 12,864,343 shares in the last quarter. Nordea Investment Management AB grew its holdings in Pfizer by 36.1% during the 4th quarter. Nordea Investment Management AB now owns 4,071,700 shares of the biopharmaceutical company's stock valued at $108,002,000 after buying an additional 1,080,822 shares in the last quarter. Parsons Capital Management Inc. RI grew its holdings in Pfizer by 118.7% during the 4th quarter. Parsons Capital Management Inc. RI now owns 294,764 shares of the biopharmaceutical company's stock valued at $7,820,000 after buying an additional 159,984 shares in the last quarter. Parnassus Investments LLC grew its holdings in Pfizer by 3.7% during the 3rd quarter. Parnassus Investments LLC now owns 4,390,705 shares of the biopharmaceutical company's stock valued at $127,067,000 after buying an additional 156,894 shares in the last quarter. Finally, TrinityPoint Wealth LLC grew its holdings in Pfizer by 85.5% during the 3rd quarter. TrinityPoint Wealth LLC now owns 191,544 shares of the biopharmaceutical company's stock valued at $5,543,000 after buying an additional 88,258 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company's stock.

Remove Ads

Insider Transactions at Pfizer

In related news, Director Ronald E. Blaylock purchased 19,457 shares of Pfizer stock in a transaction dated Thursday, February 13th. The stock was purchased at an average cost of $25.65 per share, with a total value of $499,072.05. Following the transaction, the director now owns 27,707 shares in the company, valued at approximately $710,684.55. The trade was a 235.84 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 0.06% of the company's stock.

Pfizer Stock Up 1.0 %

NYSE PFE traded up $0.26 on Tuesday, reaching $26.31. 32,949,032 shares of the stock traded hands, compared to its average volume of 35,799,303. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The company has a fifty day moving average price of $26.21 and a 200-day moving average price of $27.09. The company has a market cap of $149.09 billion, a price-to-earnings ratio of 18.66, a PEG ratio of 0.64 and a beta of 0.61. Pfizer Inc. has a 12 month low of $24.48 and a 12 month high of $31.54.

Pfizer (NYSE:PFE - Get Free Report) last issued its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, beating analysts' consensus estimates of $0.48 by $0.15. The business had revenue of $17.76 billion during the quarter, compared to analyst estimates of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. Pfizer's revenue was up 24.7% on a year-over-year basis. During the same period in the previous year, the company posted $0.10 EPS. As a group, research analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have weighed in on PFE shares. StockNews.com cut Pfizer from a "strong-buy" rating to a "buy" rating in a report on Wednesday, November 20th. Truist Financial dropped their target price on Pfizer from $36.00 to $32.00 and set a "buy" rating for the company in a report on Wednesday, December 18th. Citigroup dropped their target price on Pfizer from $30.00 to $29.00 and set a "neutral" rating for the company in a report on Tuesday, January 28th. Hsbc Global Res upgraded Pfizer to a "strong-buy" rating in a report on Monday, March 10th. Finally, Bank of America reiterated a "neutral" rating and issued a $29.00 target price on shares of Pfizer in a report on Tuesday, December 10th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, six have given a buy rating and three have issued a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $31.92.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.